Chronic Venous Insufficiency (CVI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Chronic Venous Insufficiency (CVI) Market Outlook

Thelansis’s “Chronic Venous Insufficiency (CVI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Venous Insufficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Venous Insufficiency (CVI) Overview

Chronic Venous Insufficiency (CVI) is where the venous wall and valves in the leg veins lose effectiveness, making it challenging for blood to flow back to the heart from the legs. This results in the accumulation of blood in these veins, a condition known as stasis. The causes of CVI can be categorized as either primary or secondary, with primary CVI being symptomatic without any specific triggering event, often due to congenital defects or changes in the venous wall's biochemistry. Secondary CVI, on the other hand, occurs in response to deep venous thrombosis (DVT), which initiates an inflammatory reaction, causing damage to the vein wall. Regardless of the underlying cause, CVI leads to elevated venous pressure. Several risk factors contribute to the development of CVI, including advanced age, a history of deep vein thrombosis, a sedentary lifestyle, oral contraceptives, leg injuries, and hypertension. The treatment approach for patients with chronic venous insufficiency depends on the severity and nature of the condition. The primary objectives of treatment are to alleviate discomfort and reduce swelling, stabilize the appearance of the skin, eliminate painful varicose veins, and promote the healing of ulcers. Usually, initial treatment involves conservative measures such as elevating the legs, engaging in exercises to improve calf muscle function, managing weight, and using compression therapy. It's important to note that compression therapy is a long-term solution and is effective only when patients adhere to it.

• Chronic Venous Insufficiency predominantly affects the lower limbs, with a prevalence ranging from 25% to 40% in women and 10% to 20% in men. According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses estimate that 2.3-6.2% of all residents of the USA have some changes associated with CVI.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: